Cargando…
Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
BACKGROUND: Quantitative skeletal muscle mass loss has the potential to predict the therapeutic effects of immune checkpoint inhibitors. This study aimed to assess the impact of muscular quality on the abovementioned outcomes. METHODS: This study retrospectively reviewed the medical records of patie...
Autores principales: | Nishioka, Naoya, Naito, Tateaki, Notsu, Akifumi, Mori, Keita, Kodama, Hiroaki, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Takayama, Koichi, Takahashi, Toshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826480/ https://www.ncbi.nlm.nih.gov/pubmed/33300678 http://dx.doi.org/10.1002/cam4.3631 |
Ejemplares similares
-
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021) -
Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
por: Miyawaki, Taichi, et al.
Publicado: (2020) -
Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020) -
Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022) -
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)